Difference between revisions of "SUIT-037 O2 mt D090"
Line 1: | Line 1: | ||
{{MitoPedia | {{MitoPedia | ||
|abbr= | |abbr=FAO(Oct) & M kinetics | ||
|description=[[File:1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp;9U;10Rot;11Ama.png|400px]] | |description=[[File:1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp;9U;10Rot;11Ama.png|400px]] | ||
|info='''A''' - '''[[SUIT-037]]''' - ''' | |info='''A''' - '''[[SUIT-037]]''' - '''[[Fatty_acid_oxidation_pathway_control_state|F-pathway]] and [[Malic_enzyme|malate anaplerosis]]''' | ||
|application=O2 | |application=O2 | ||
|SUIT number=D090_1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp;9U;10Rot;11Ama | |SUIT number=D090_1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp;9U;10Rot;11Ama | ||
Line 10: | Line 10: | ||
__TOC__ | __TOC__ | ||
Communicated by [[ | Communicated by [[Grings M]], [[Cecatto C]] and [[Cardoso LHD]] (last update 2023-04-12) | ||
== Representative traces == | == Representative traces == | ||
Line 19: | Line 19: | ||
== Strengths and limitations == | == Strengths and limitations == | ||
:::* SUIT- | :::* SUIT-037 in combination with [[SUIT-036]] and [[SUIT-038]] provides a basis to study fatty acid oxidation (FAO) in a large variety of species, tissues and cell types. These protocols in combination allow: | ||
:::: 1. to | :::: 1. to assess FAO carefully avoiding overestimation by endogenous substrates or malate anaplerosis. | ||
:::: 2. to | :::: 2. to compare FAO with palmitoylcarnitine or octanoylcarnitine. | ||
:::: 3. to | :::: 3. to analyse malate anaplerosis with malate kinetics | ||
::: | :::: 4. to analyse OXPHOS respiration and ET-capacity with various pathways (F, N, S, Gp) | ||
:::* A succinate concentration of >10 mM may be required for saturating S<sub>''E''</sub> capacity. | :::* A succinate concentration of >10 mM may be required for saturating S<sub>''E''</sub> capacity. | ||
:::+ SUIT- | :::+ SUIT-037 allows the depletion of endogenous substrates with ADP (1D). | ||
:::+ The protocol provides information on F-pathway in OXPHOS state. The low concentration of malate used in this protocol, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway. | :::+ The protocol provides information on F-pathway in OXPHOS state. The low concentration of malate used in this protocol, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway. | ||
:::+ F-pathway (3Oct-2M.1) can be compared to FN-pathway (5P) in OXPHOS state. | :::+ F-pathway (3Oct-2M.1) can be compared to FN-pathway (5P) in OXPHOS state. | ||
Line 37: | Line 37: | ||
:::- S-pathway in ET state is not obtained (it is obtained in [[SUIT-001]]). | :::- S-pathway in ET state is not obtained (it is obtained in [[SUIT-001]]). | ||
:::- Lengthy duration of the experiment. | :::- Lengthy duration of the experiment. | ||
:::- We do not generally | :::- We do not generally recommend the addition of already permeabilized cells, but we recommend to perform the permeabilization of the cell plasma membrane in the chambers (see [[SUIT-002 O2 ce-pce D007]]). | ||
== Compare SUIT protocols == | == Compare SUIT protocols == |
Revision as of 12:22, 12 April 2023
Description
Abbreviation: FAO(Oct) & M kinetics
Reference: A - SUIT-037 - F-pathway and malate anaplerosis
SUIT number: D090_1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp;9U;10Rot;11Ama
O2k-Application: O2
The SUIT-037 O2 mt D090 protocol provides a common reference for comparison of respiratory control of mitochondrial preparations such as isolated mitochondria, tissue homogenates and permeabilized cells (already permeabilized when they are added to the chamber) in a wide variety of species, tissues and cell types. SUIT-037 O2 mt D090 is specially designed to give information on F-pathway with octanoylcarnitine as a FAO substrate in OXPHOS state avoiding FAO overestimation in the presence of anaplerotic pathways. The careful titration of malate is required to analyze the activity of the mt-isoform of NADP- or NAD(P)-dependent malic enzyme (mtME). Moreover, the pathway control in OXPHOS state (F, F(N), FN, FNS, FNSGp pathways) and in ET state (FNSGp and SGp) can be evaluated by using this SUIT protocol.
Communicated by Grings M, Cecatto C and Cardoso LHD (last update 2023-04-12)
Representative traces
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1D | ROX | 1D
| ||
2M.1 | 1D;2M.1 | |||
3Oct | OctMP | F | FAO | 1D;2M.1;3Oct
|
3c | OctMcP | F | FAO | 1D;2M.1;3Oct;3c
|
4M.2 | OctMP | F(N) | FAO | 1D;2M.1;3Oct;3c;4M.2
|
4M.5 | OctMP | F(N) | FAO | 1D;2M.1;3Oct;3c;4M.2;4M.5
|
4M1 | OctMP | F(N) | FAO | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1
|
4M2 | OctMP | F(N) | FAO | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2
|
5P | OctPMP | FN | FAO&CI | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P
|
6G | OctPGMP | FN | FAO&CI | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G
|
7S10 | OctPGMSP | FNS | FAO&CI&II | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10
|
7S50 | OctPGMSP | FNS | FAO&CI&II | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50
|
8Gp | OctPGMSGpP | FNSGp | FAO&CI&II&GpDH | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp
|
9U | OctPGMSGpE | FNSGp | FAO&CI&II&GpDH | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp;9U
|
10Rot | SGpE | SGp | CII&GpDH | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp;9U;10Rot
|
11Ama | ROX | 1D;2M.1;3Oct;3c;4M.2;4M.5;4M1;4M2;5P;6G;7S10;7S50;8Gp;9U;10Rot;11Ama
|
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- Main fuel substrates
- » Glutamate, G
- » Glycerophosphate, Gp
- » Malate, M
- » Octanoylcarnitine, Oct
- » Pyruvate, P
- » Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- SUIT-037 in combination with SUIT-036 and SUIT-038 provides a basis to study fatty acid oxidation (FAO) in a large variety of species, tissues and cell types. These protocols in combination allow:
- 1. to assess FAO carefully avoiding overestimation by endogenous substrates or malate anaplerosis.
- 2. to compare FAO with palmitoylcarnitine or octanoylcarnitine.
- 3. to analyse malate anaplerosis with malate kinetics
- 4. to analyse OXPHOS respiration and ET-capacity with various pathways (F, N, S, Gp)
- A succinate concentration of >10 mM may be required for saturating SE capacity.
- + SUIT-037 allows the depletion of endogenous substrates with ADP (1D).
- + The protocol provides information on F-pathway in OXPHOS state. The low concentration of malate used in this protocol, typically 0.1 mM, does not saturate the N-pathway; but saturates the F-pathway.
- + F-pathway (3Oct-2M.1) can be compared to FN-pathway (5P) in OXPHOS state.
- + Pathway control in OXPHOS (F, F(N), FN, FNS, FNSGp pathways) and in ET state (FNSGp and SGp) can be observed.
- + Harmonization with SUIT-001 allows to perform both SUIT protocols in parallel. The cross-linked respiratory states can be statistically used as repeated measurements.
- + Harmonization with many SUIT protocols (up to step 7S).
- + In SUIT-002, the full set of pathways converging into Q (FNSGp) is obtained in OXPHOS and ET states. Therefore, P/E (8Gp/9U) at high ET capacity can be calculated.
- + This protocol can be extended with the Complex IV module.
- - S-pathway in ET state is not obtained (it is obtained in SUIT-001).
- - Lengthy duration of the experiment.
- - We do not generally recommend the addition of already permeabilized cells, but we recommend to perform the permeabilization of the cell plasma membrane in the chambers (see SUIT-002 O2 ce-pce D007).
Compare SUIT protocols
- SUIT-001 O2 mt D001 (RP1): Harmonized SUIT protocol for isolated mitochondria, tissue homogenate and permeabilized cells (already permeabilized).
- SUIT-002 O2 ce-pce D007: SUIT-002 for non-permeabilized cells. Permeabilization of the cell plasma membrane occurs in the chambers through digitonin addition. Therefore, SUIT-002 O2 ce-pce D007 protocol provides information of non-permeabilized cell respiration (ce) and permeabilized cell respiration (pce).
Chemicals and syringes
Step | Chemical(s) and link(s) | Comments |
---|---|---|
1D | ADP (D) | |
2M.1 | Malate (M) | |
3Oct | Octanoylcarnitine (Oct) | |
3c | Cytochrome c (c) | |
4M.2 | Malate (M) | |
4M.5 | Malate (M) | |
4M1 | Malate (M) | |
4M2 | Malate (M) | |
5P | Pyruvate (P) | |
6G | Glutamate (G) | |
7S10 | Succinate (S) | |
7S50 | Succinate (S) | |
8Gp | Glycerophosphate (Gp) | |
9U | Carbonyl cyanide m-chlorophenyl hydrazone, CCCP (U) | Can be substituted for other uncoupler |
10Rot | Rotenone (Rot) | |
11Ama | Antimycin A (Ama) |
- Suggested stock concentrations are shown in the specific DL-Protocol.